Condition 1: Diabetes. Condition 2: Hypertension. Type 2 diabetes mellitus Essential (primary) hypertension
Conditions
Interventions
Intervention 1: Intervention group: 1 vitamin D capsule daily containing 2000 IU of cholecalciferol manufactured by Nanohyat pharmaceutical company, Iran. Intervention 2: Control group: 1 capsule dail
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: At least 5 years diabetes history based on self-reported Diabetes control with metformin, Glibenclamide, glitazone, Gliclazide or a combination of these Blood pressure control with any of the Angiotensin receptor blockers (ARB), ACE Inhibitor, Calcium channel blockers (CCB), Thiazide diuretics or a combination of these
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Gastrointestinal diseases such as malabsorption History of cardiovascular problems Kidney? liver and other endocrine diseases Malignancy Type 1 diabetes BMI<40 The consumption of vitamin D and multivitamin mineral supplements over the past 3 months Drugs affecting vitamin D and calcium metabolism, Insulin therapy Weight loss medications such as Orlistat
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated dilatation changes. Timepoint: At baseline and week12. Method of measurement: Ultrasonography.;ICAM1. Timepoint: At baseline and week 12. Method of measurement: Serum level measurement using ELISA kit.;Oxidized LDL. Timepoint: At baseline and week 12. Method of measurement: Serum level measurement using ELISA kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReyhaneh Ghasemi
Oroumia University of Medical Sciences
Outcome results
None listed